Skip to main content
Premium Trial:

Request an Annual Quote

Emerald Organic Products, Todos Medical Form Coronavirus Test JV

NEW YORK – Emerald Organic Products and Todos Medical said Tuesday that they have formed a joint venture, Corona Diagnostics, to provide screening assays and diagnostic tests for COVID-19 in the US.

Financial and other terms of the deal were not disclosed.

Emerald Organic, a diversified health sciences company, will contribute financing, US domestic distribution know-how, international trade relationships, and assistance in navigating the US healthcare and regulatory landscape, the firms said.

Todos will be responsible for securing regulatory approval from the US Food and Drug Administration for a rapid point-of-care kit, Colloidal Gold, that detects antibodies to SARS-CoV-2, the coronavirus that causes COVID-19. Last week, Todos said it had inked an exclusive agreement with Gibraltar Brothers & Associates, a US-based subsidiary of China-based Shanghai Liangrun Biomedicine Technology, to distribute Colloidal Gold in the US and Israel.

Further, Corona Diagnostics will leverage an agreement that Todos has inked with 3D Medicines for distribution of its Andis SARS-CoV-2 Detection Kit, Andis SARS-CoV-2 & Influenza A/B Detection Kit, and Andis 350 3DMed Automated Solution countertop real-time PCR machine.

Corona Diagnostics anticipates launching the automated PCR-based test in combination with Colloidal Gold.

By combining its efforts with those of Todos, Emerald Organic is taking aim at helping "relieve bottlenecks" in the PCR testing process by enabling screening of patients with the rapid point-of-care tests, its CEO Ian Parker said in a statement.

New York City-based Emerald will own 51 percent and Rehovot, Israel-based Todos will own 49 percent of the joint venture.

The Scan

Study Tracks Off-Target Gene Edits Linked to Epigenetic Features

Using machine learning, researchers characterize in BMC Genomics the potential off-target effects of 19 computed or experimentally determined epigenetic features during CRISPR-Cas9 editing.

Coronary Artery Disease Risk Loci, Candidate Genes Identified in GWAS Meta-Analysis

A GWAS in Nature Genetics of nearly 1.4 million coronary artery disease cases and controls focused in on more than 200 candidate causal genes, including the cell motility-related myosin gene MYO9B.

Multiple Sclerosis Contributors Found in Proteome-Wide Association Study

With a combination of genome-wide association and brain proteome data, researchers in the Annals of Clinical and Translational Neurology tracked down dozens of potential multiple sclerosis risk proteins.

Quality Improvement Study Compares Molecular Tumor Boards, Central Consensus Recommendations

With 50 simulated cancer cases, researchers in JAMA Network Open compared molecular tumor board recommendations with central consensus plans at a dozen centers in Japan.